17 results about "Muscle relaxant" patented technology

The topical composition is for application to a portion of skin at a locus of postsurgical pain and comprises: an amount of anti-inflammatory analgesic; an amount of muscle relaxant; an amount of neuropathic analgesic; an amount of anesthetic; and a carrier having skin penetration enhancement qualities.

1. Name of the product in this design: Side-view muscle relaxer. 2. Intended use of this design: massage equipment. 3. The key design features of this product are the combination of shape and pattern. 4. The image or photograph that best illustrates the design's key points: 3D view 1. 5. The bottom view is symmetrical to the top view, so the bottom view is omitted.

The present invention discloses a cyclopropylmethyl steroid quaternary ammonium salt compound represented by formula (I) and a preparation method thereof. Such compounds can be used to prepare non-depolarizing short-acting muscle relaxants. Compared with rocuronium bromide widely used clinically at present, the onset and duration of action of this short-acting muscle relaxant are similar, but the drug metabolism is significantly faster, the muscle relaxation time is significantly shortened, and it has better safety, and is expected to greatly reduce the high incidence of postoperative residual muscle relaxation effect that seriously affects the safety of postoperative patients.

The invention relates to besylate salts of the compound of formula (I):Methods of preparing the salts, and their use as medicaments, in particular for sedative or hypnotic, anxiolytic, muscle relaxant, or anticonvulsant purposes is also described.

The invention relates to besylate salts of the compound of formula (I):Methods of preparing the salts, and their use as medicaments, in particular for sedative or hypnotic, anxiolytic, muscle relaxant, or anticonvulsant purposes is also described.

The invention discloses a supramolecular antagonist as well as a preparation method and application thereof, and belongs to the technical field of medical preparations containing organic effective components. The supramolecular antagonist comprises one of water-soluble carboxylate pillar [5] arene or phosphate pillar [5] arene, the binding property of the supramolecular antagonist and decabromyl ammonium bromide is excellent, the chain length of a main body branch chain of the supramolecular antagonist has obvious influence on the muscle relaxation effect, different types of supramolecular antagonists can be flexibly selected, and the supramolecular antagonist can be applied to the field of muscle relaxation. And estimating the muscle relaxation effect of the muscle relaxation agent from the structure matching property. The synthesis method of the supramolecular antagonist, provided by the invention, has the advantages of simplicity and convenience in operation, high efficiency and wide raw material source, and is beneficial to expanded production and preparation of the supramolecular antagonist. The supramolecular antagonist is used as an antagonist of decabonium bromide, and is combined with decabonium bromide through a host compound, so that muscle relaxation reversal of decabonium bromide is realized, and the supramolecular antagonist has a wide application prospect.

The application relates to a preparation method of the muscle relaxant succinylcholine sodium, which comprises the following steps: adopting gamma-cyclodextrin, carrying out total halogenation, and then reacting with potassium thioacetate to prepare a key intermediate compound 6-full deoxy-6-full thioacetate-gamma-cyclodextrin, and then directly reacting with acrylic acid through one-pot synthesis to prepare succinylcholine sodium. The application has the advantages of mild reaction condition, simple post-treatment operation, good process reproducibility and high yield.

1. The name of the design product: high frequency muscle relaxant gun. 2. The use of the design product: for human muscle massage. 3. The design points of the design product: in shape. 4. The picture or photo that best shows the design points: design 1 perspective view. 5. Design 1 is designated as the basic design.

The present invention discloses a muscle relaxant antagonist composition, according to mass volume ratio, including 0.5mg / ml active ingredient, 8mg / ml-10mg / ml isotonic agent, 2mg / ml-4mg / ml sulfobutyl ether-β-cyclodextrin, appropriate pH adjusting agent, the remaining water for injection, and the composition pH value are 3.5-4.5. Especially when pH is 3.7-4.0, impurity A content can be controlled at less than 0.1%;In addition, the inventors also unexpectedly found that when pH is about 3.8, impurity A can be controlled at less than 0.05%. In short, the present invention has the advantages of high product quality, good stability, simple preparation method, etc.

The application provides a kind of diazacyclic compound and its use. Specifically provided is a compound V, a pharmaceutically acceptable salt thereof, a solvate thereof, a metabolite thereof, a tautomer thereof or a prodrug thereof;The compound V comprises a compound shown in formula I and a pharmaceutically acceptable anion. The compound V provided by the application is simple in structure, can be used to prepare muscle relaxant, and has good application prospect.

This invention relates to the fields of biotechnology and pharmacogenomics detection, and discloses a kit and application for gene detection of drugs used in general anesthesia. The kit contains a primer set for detecting genetic polymorphic loci related to commonly used perioperative anesthetic, analgesic, and muscle relaxant drugs. The primer set includes multiplex PCR amplification primers and single-base extension primers. The kit also includes multiplex PCR amplification reaction solution, SAP reaction solution, SAP enzyme, extension buffer, single-base extension termination mixture, extension reaction enzyme, desalting purification resin, standards, calibrators, deionized water, and instructions for use. This invention uses matrix-assisted laser desorption / ionization time-of-flight mass spectrometry (MALDI-TOF) to genotype SNP loci, obtaining genotype results for 103 genetic polymorphic loci in a single test. This allows for the prediction of individual differences in drug metabolism, drug efficacy, and adverse reaction risk, providing a basis for personalized medication in general anesthesia.

To provide a method capable of non-invasively visualizing and recording membrane potentials of neuronal populations and individual neurons in zebrafish in real time and over a long period of time.SOLUTION: A method involves observing embryos obtained by crossing zebrafish individuals which express ArcLight at high brightness selected from an ArcLight gene-introduced zebrafish population. These embryos are reared at 23°C under either a 14-hour light / 10-hour dark cycle or continuous darkness for 24 hours, and 30 minutes prior to sample preparation on the day of recording, the rearing temperature is changed to 28.5°C. The embryos are treated with a muscle relaxant to prevent movement during observation, mounted in low-melting-point agarose, and membrane potentials are observed and recorded using a fluorescence microscope.SELECTED DRAWING: Figure 6

The present invention discloses the application of acu-chlorammonium in the preparation of drugs for treating cardiac arrhythmias. The invention first discovered that acu-chlorammonium can effectively act as an IK1-specific agonist, exhibiting effects similar to zacopride. Therefore, it can be used in the preparation of anti-arrhythmic drugs, thus providing a new and effective, safe treatment approach.

Disclosed are deuterated glycoluril tetramer compounds having aryl groups incorporated at both ends represented by formula (1), pharmaceutical compositions containing the compounds. The deuterated compounds are useful for antagonizing clinically used non-depolarizing muscle relaxants, and have significantly superior antagonistic activity against rocuronium and vecuronium to sugammadex at the same dose, and significantly superior antagonistic activity against cisatracurium and rocuronium to a non-deuterated control molecule.